Press Releases SAB Biotherapeutics, Inc.

Equities

SABS

US78397T2024

Market Closed - Nasdaq Other stock markets 16:30:01 2024-05-14 EDT			5-day change	1st Jan Change
4.045 ^USD	-1.10%		-1.10%	-41.16%

05-06	SAB Biotherapeutics, Inc. Appoints Jay Skyler, Md, to the Board of Directors	CI
04-16	SAB Biotherapeutics, Inc. Provides SAB-142 Trial Update	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors	05-06	AQ
SAB Biotherapeutics Provides SAB-142 Trial Update	04-16	AQ
SAB Biotherapeutics : Regulation FD Disclosure - Form 8-K	04-15	PU
SAB Biotherapeutics to Present at INNODIA Annual Meeting	04-08	AQ
SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference	04-04	AQ
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results	04-01	AQ
SAB Biotherapeutics : Reports Full Year 2023 Operating and Financial Results March 29, 2024 - Form 8-K	03-29	PU
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results	03-29	AQ
SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment	03-25	AQ
SAB Biotherapeutics to Present at the BIO CEO and Investor Conference	02-26	AQ
SAB Biotherapeutics to Present at the BIO CEO & Investor Conference	02-23	AQ
SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	02-09	AQ
SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	02-08	AQ
SAB Biotherapeutics Announces Executive Leadership Change	02-02	AQ
SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement	01-23	AQ
SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split	01-02	GL
SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes	11-30	AQ
SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes	11-29	AQ
SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors	11-20	GL
SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes	11-14	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases SAB Biotherapeutics, Inc.

Equities

SABS

US78397T2024

Press Releases

Filters